- Home
- LILAK vs NVAX Comparison
LILAK vs NVAX Comparison
Compare LILAK & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LILAK
- NVAX
- Stock Information
- Founded
- LILAK 2017
- NVAX 1987
- Country
- LILAK Bermuda
- NVAX United States
- Employees
- LILAK N/A
- NVAX N/A
- Industry
- LILAK Cable & Other Pay Television Services
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LILAK Telecommunications
- NVAX Health Care
- Exchange
- LILAK Nasdaq
- NVAX Nasdaq
- Market Cap
- LILAK 1.1B
- NVAX 1.3B
- IPO Year
- LILAK N/A
- NVAX 1995
- Fundamental
- Price
- LILAK $6.43
- NVAX $6.60
- Analyst Decision
- LILAK Buy
- NVAX Buy
- Analyst Count
- LILAK 3
- NVAX 5
- Target Price
- LILAK $10.27
- NVAX $16.60
- AVG Volume (30 Days)
- LILAK 1.0M
- NVAX 5.5M
- Earning Date
- LILAK 08-05-2025
- NVAX 08-07-2025
- Dividend Yield
- LILAK N/A
- NVAX N/A
- EPS Growth
- LILAK N/A
- NVAX N/A
- EPS
- LILAK N/A
- NVAX 2.97
- Revenue
- LILAK $4,441,000,000.00
- NVAX $1,254,962,000.00
- Revenue This Year
- LILAK $2.45
- NVAX $56.85
- Revenue Next Year
- LILAK $3.11
- NVAX N/A
- P/E Ratio
- LILAK N/A
- NVAX $2.22
- Revenue Growth
- LILAK N/A
- NVAX 25.92
- 52 Week Low
- LILAK $4.23
- NVAX $5.01
- 52 Week High
- LILAK $10.93
- NVAX $17.81
- Technical
- Relative Strength Index (RSI)
- LILAK 71.55
- NVAX 42.34
- Support Level
- LILAK $5.78
- NVAX $6.26
- Resistance Level
- LILAK $6.09
- NVAX $6.60
- Average True Range (ATR)
- LILAK 0.25
- NVAX 0.27
- MACD
- LILAK 0.09
- NVAX -0.06
- Stochastic Oscillator
- LILAK 92.13
- NVAX 15.94
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.